TearScience has received the US Food and Drug Administration (FDA) approval for its LipiFlow Thermal Pulsation System to treat evaporative dry eye caused by meibomian gland dysfunction (MGD) and a lipid deficiency of the eye’s natural tear film.
TearScience has been awarded FDA approval through a nine-center randomized controlled clinical trial which demonstrated the safety and effectiveness of LipiFlow.
LipiFlow applies directed energy to a patient’s eyelid and takes out MGD obstructions during a 12-minute in-office treatment.
TearScience will sell its LipiFlow and LipiView Ocular Surface Interferometer devices as a system for eye care practices.
The LipiView enables physicians to visualize the eye’s tear film.